192 related articles for article (PubMed ID: 37804003)
1. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Kim HJ; Aktas O; Patterson KR; Korff S; Kunchok A; Bennett JL; Weinshenker BG; Paul F; Hartung HP; Cimbora D; Smith MA; Mittereder N; Rees WA; She D; Cree BAC
Ann Clin Transl Neurol; 2023 Dec; 10(12):2413-2420. PubMed ID: 37804003
[TBL] [Abstract][Full Text] [Related]
2. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
3. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
4. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
5. Inebilizumab: First Approval.
Frampton JE
Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
[TBL] [Abstract][Full Text] [Related]
6. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
[TBL] [Abstract][Full Text] [Related]
7. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Rensel M; Zabeti A; Mealy MA; Cimbora D; She D; Drappa J; Katz E
Mult Scler; 2022 May; 28(6):925-932. PubMed ID: 34595983
[TBL] [Abstract][Full Text] [Related]
9. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder).
Ali F; Sharma K; Anjum V; Ali A
Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260
[TBL] [Abstract][Full Text] [Related]
10. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V; Flanagan EP
Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
[TBL] [Abstract][Full Text] [Related]
13. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Yan L; Wang B; She D; Mitchell B; Criste R; Cimbora D; Katz E; Rees WA
Br J Clin Pharmacol; 2022 Aug; 88(8):3803-3812. PubMed ID: 35332558
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
19. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
20. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
